Literature DB >> 34956484

MiR-103a-3p aggravates renal cell carcinoma by targeting TMEM33.

Jingyu Zhang1, Qingbo Lu2, Haigang Pang3, Min Zhang4, Wenhai Wei5.   

Abstract

OBJECTIVE: We investigated the mechanism of miR-103a-3p-mediated renal cell carcinoma (RCC) progression.
METHODS: The miR-103a-3p expressions were measured in clinical samples and in two RCC cell lines. MiR-103a-3p was inhibited or over-expressed in the 786-O and UO31 cell lines, respectively.
RESULTS: We found that miR-103a-3p is closely related to the development of RCC cells. A bioinformatics analysis and a dual-luciferase reporter gene assay revealed that there is a direct interaction between TMEM33 and miR-103a-3p. Moreover, a rescue assay further confirmed that TMEM33 overexpression can attenuate miR-103a-3p-induced RCC cell development.
CONCLUSION: miR-103a-3p exerts a carcinogenic function in RCC by regulating TMEM33, a finding that may provide new insights into the development of prognostic markers and therapeutic targets for RCC. AJTR
Copyright © 2021.

Entities:  

Keywords:  Renal cell carcinoma; TMEM33; metastasis; miR-103a-3p; proliferation

Year:  2021        PMID: 34956484      PMCID: PMC8661195     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  23 in total

Review 1.  MicroRNA: function, detection, and bioanalysis.

Authors:  Haifeng Dong; Jianping Lei; Lin Ding; Yongqiang Wen; Huangxian Ju; Xueji Zhang
Journal:  Chem Rev       Date:  2013-05-22       Impact factor: 60.622

2.  Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.

Authors:  B Escudier; C Porta; M Schmidinger; N Rioux-Leclercq; A Bex; V Khoo; V Grünwald; S Gillessen; A Horwich
Journal:  Ann Oncol       Date:  2019-05-01       Impact factor: 32.976

3.  Cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-01-08       Impact factor: 508.702

4.  Inhibition of miR-103a-3p suppresses the proliferation in oral squamous cell carcinoma cells via targeting RCAN1.

Authors:  G Zhang; Z Chen; Y Zhang; T Li; Y Bao; S Zhang
Journal:  Neoplasma       Date:  2020-02-28       Impact factor: 2.575

5.  miR-103a-3p Suppresses Cell Proliferation and Invasion by Targeting Tumor Protein D52 in Prostate Cancer.

Authors:  Jiyue Ge; Likai Mao; Weiqiang Xu; Wenge Fang; Ningning Wang; Dawen Ye; Zhuang Dong; Han Guan; Chao Guan
Journal:  J Invest Surg       Date:  2020-03-13       Impact factor: 2.533

6.  MiR-103a-3p targets the 5' UTR of GPRC5A in pancreatic cells.

Authors:  Honglei Zhou; Isidore Rigoutsos
Journal:  RNA       Date:  2014-07-01       Impact factor: 4.942

Review 7.  Renal cell carcinoma.

Authors:  Eric Jonasch; Jianjun Gao; W Kimryn Rathmell
Journal:  BMJ       Date:  2014-11-10

8.  MiR-543 promotes cell proliferation and metastasis of renal cell carcinoma by targeting Dickkopf 1 through the Wnt/β-catenin signaling pathway.

Authors:  Zhi-Yuan Chen; Yang Du; Lei Wang; Xiu-Heng Liu; Jia Guo; Xiao-Dong Weng
Journal:  J Cancer       Date:  2018-09-08       Impact factor: 4.207

9.  MOV10 binding circ-DICER1 regulates the angiogenesis of glioma via miR-103a-3p/miR-382-5p mediated ZIC4 expression change.

Authors:  Qianru He; Lini Zhao; Xiaobai Liu; Jian Zheng; Yunhui Liu; Libo Liu; Jun Ma; Heng Cai; Zhen Li; Yixue Xue
Journal:  J Exp Clin Cancer Res       Date:  2019-01-08

10.  tmem33 is essential for VEGF-mediated endothelial calcium oscillations and angiogenesis.

Authors:  Aaron M Savage; Sathishkumar Kurusamy; Yan Chen; Zhen Jiang; Karishma Chhabria; Ryan B MacDonald; Hyejeong R Kim; Heather L Wilson; Fredericus J M van Eeden; Angel L Armesilla; Timothy J A Chico; Robert N Wilkinson
Journal:  Nat Commun       Date:  2019-02-13       Impact factor: 14.919

View more
  1 in total

Review 1.  Immunomodulatory Properties of Human Breast Milk: MicroRNA Contents and Potential Epigenetic Effects.

Authors:  Ma'mon M Hatmal; Mohammad A I Al-Hatamleh; Amin N Olaimat; Walhan Alshaer; Hanan Hasan; Khaled A Albakri; Enas Alkhafaji; Nada N Issa; Murad A Al-Holy; Salim M Abderrahman; Atiyeh M Abdallah; Rohimah Mohamud
Journal:  Biomedicines       Date:  2022-05-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.